Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
94.95
+2.86 (3.11%)
Mar 9, 2026, 1:59 PM EDT - Market open
Protagonist Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 46.02 | 434.43 | 60 | 26.58 | 27.36 | Upgrade
|
| Revenue Growth (YoY) | -89.41% | 624.05% | 125.72% | -2.84% | -4.44% | Upgrade
|
| Gross Profit | 46.02 | 434.43 | 60 | 26.58 | 27.36 | Upgrade
|
| Selling, General & Admin | 44.85 | 43.46 | 33.49 | 31.74 | 27.2 | Upgrade
|
| Research & Development | 159.29 | 138.13 | 120.16 | 126.22 | 126.01 | Upgrade
|
| Operating Expenses | 204.14 | 181.59 | 153.65 | 157.95 | 153.2 | Upgrade
|
| Operating Income | -158.13 | 252.84 | -93.65 | -131.37 | -125.85 | Upgrade
|
| Interest & Investment Income | 28.79 | 26.32 | 14.9 | 4.06 | 0.44 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | -0.08 | -0.15 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.03 | 0.25 | -0.2 | - | - | Upgrade
|
| EBT Excluding Unusual Items | -129.31 | 279.41 | -78.96 | -127.39 | -125.55 | Upgrade
|
| Pretax Income | -129.31 | 279.41 | -78.96 | -127.39 | -125.55 | Upgrade
|
| Income Tax Expense | 0.84 | 4.22 | - | - | - | Upgrade
|
| Net Income | -130.15 | 275.19 | -78.96 | -127.39 | -125.55 | Upgrade
|
| Net Income to Common | -130.15 | 275.19 | -78.96 | -127.39 | -125.55 | Upgrade
|
| Shares Outstanding (Basic) | 64 | 62 | 57 | 49 | 46 | Upgrade
|
| Shares Outstanding (Diluted) | 64 | 65 | 57 | 49 | 46 | Upgrade
|
| Shares Change (YoY) | -2.31% | 14.65% | 15.74% | 5.87% | 34.67% | Upgrade
|
| EPS (Basic) | -2.05 | 4.47 | -1.39 | -2.60 | -2.71 | Upgrade
|
| EPS (Diluted) | -2.05 | 4.23 | -1.39 | -2.60 | -2.71 | Upgrade
|
| Free Cash Flow | 56.08 | 182.8 | -70.85 | -108.93 | -108.97 | Upgrade
|
| Free Cash Flow Per Share | 0.88 | 2.81 | -1.25 | -2.22 | -2.35 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -343.63% | 58.20% | -156.09% | -494.24% | -460.01% | Upgrade
|
| Profit Margin | -282.83% | 63.34% | -131.59% | -479.26% | -458.94% | Upgrade
|
| Free Cash Flow Margin | 121.87% | 42.08% | -118.08% | -409.81% | -398.31% | Upgrade
|
| EBITDA | -156.85 | 253.67 | -92.68 | -130.34 | -125.03 | Upgrade
|
| EBITDA Margin | - | 58.39% | -154.46% | - | - | Upgrade
|
| D&A For EBITDA | 1.28 | 0.83 | 0.98 | 1.03 | 0.81 | Upgrade
|
| EBIT | -158.13 | 252.84 | -93.65 | -131.37 | -125.85 | Upgrade
|
| EBIT Margin | - | 58.20% | -156.09% | - | - | Upgrade
|
| Effective Tax Rate | - | 1.51% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.